None of the supplied claim-level records include the Hokkaido Study (a Japanese birth cohort), child neurodevelopmental or health outcomes, or any confounder-adjustment analyses (e.g., maternal smoking, income, parity, breastfeeding). What is supplied instead: in vitro PFOS/PFOA/PFNA cytotoxicity in H4/TLT cells; PFAS class-based regulation commentary; a Maine beef-cattle toxicokinetic model; mouse bile-acid cholestasis from PFNA; marine-mammal liver PFAS; U.S. breast-milk PFAS trends; trimester-specific maternal-placental-cord PFAS transfer; and an ambient PFAS analytical method.
The nearest human-exposure record shows transplacental transfer efficiency rising across pregnancy (e.g., PFNA 43.4%β72.1%; PFOS 27.9%β36.1%) but reports no child outcomes and no confounding checks .
To battle-test the actual claim, please supply the Hokkaido Study full text (e.g., Kishi et al. birth-cohort papers) so effect estimates, covariate sets, sensitivity analyses, and exposure windows can be evaluated.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.